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combined in- and outpatient observational study in
Germany. 646 adult schizophrenia patients treated with
either olanzapine (N = 416) or haloperidol (N = 230)
were enrolled in the study and quarterly observations on
the disease course, resource consumption and quality of
life are made during the follow-up period. RESULTS: In
both treatment groups nearly 50% of the patients were
female, had been diagnosed around the age of 30 years,
and were overweight (BMI > 25). Hospital inpatients and
hospital day care patients were more severely ill (N = 230,
>50% with CGI clearly ill or worse) than outpatients (N
= 416, >50% with CGI moderate or better). For both
treatment groups the global disease severity was similar
(approximately 70% moderate or worse, 15% severe or
worse) as well as the existence of positive symptoms
(about 64% had current positive symptoms in both
groups). Olanzapine patients were younger (mean 39 vs.
46 years). Current negative symptoms (90% vs. 98%)
and cognitive symptoms (88% vs. 95%) were less
common for olanzapine patients than for haloperidol
patients, whereas depressive symptoms were more
common (75% vs. 69%). More olanzapine patients were
able to care for themselves (87% vs. 78%) and lived at
home without care (57% vs. 40%). More olanzapine
patients were employed (32% vs. 18%) and fewer were
in early retirement (27% vs. 46%). CONCLUSIONS: At
time of enrolment in the GEO observational study 
olanzapine and haloperidol-treated patients had schizo-
phrenia of similar severity but different disease course.
Fewer olanzapine patients had negative or cognitive
symptoms whereas more had depressive symptoms. More
olanzapine patients were employed and able to care for
themselves, whereas more haloperidol patients were in
early retirement.
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OBJECTIVES: To provide a study description and 
baseline socio-demographic, socio-economic and clinical
characteristics of schizophrenia patients treated with
haloperidol, olanzapine or risperidone at time of 
enrolment in the SOS observational study. METHODS:
SOS is a non-randomised 2-year prospective observa-
tional study. Data are collected on treatment costs, 
efﬁcacy, tolerability and patient quality of life using an
internet-based case report form on patients assigned treat-
ment with haloperidol, olanzapine or risperidone during
a recent psychotic episode requiring hospitalisation.
Patients were included within one month from discharge
to part-time hospitalisation or ambulatory care if treat-
ment with the study drug was stable since at least a
month. Data are collected at inclusion and after 3, 6, 12,
18 and 24 months. RESULTS: 323 patients diagnosed
with schizophrenia or schizofreniform disorders (DSM-
IV criteria) have been enrolled in the study. Preliminary
baseline data on 305 patients (males: 65%) show that 32
patients are on haloperidol, 141 on olanzapine and 132
on risperidone. 77% are outpatients. 57% suffer para-
noid schizophrenia. Mean age is 37 ± 13y. The socio-
economic proﬁle (living environment, schooling back-
ground and working activity) is comparable between
treatment groups. “Brief Psychiatric Rating Scale” and
“Clinical Global Impression” scores (overall mean: 32 ±
16 and 4.0 ± 1.2 respectively) are comparable for all
groups. However, some variables such as ﬁrst antipsy-
chotic prescription (haloperidol: 6.3%; olanzapine: 18%;
risperidone: 24%) suggest that there may be differences
between the treatment groups. “Global Assessment of
Functioning” score (mean: 52 ± 14) is signiﬁcantly lower
in the haloperidol group (47 ± 12). General quality of life
(EQ-5D) is comparable for all groups (66 ± 19). “Sub-
jective Well-Being under Neuroleptics” scores are signiﬁ-
cantly worse in the olanzapine group. CONCLUSION:
The SOS observational study will provide substantial
information to increase the understanding of the clinical,
social and economic outcomes and current treatment
modalities in real world clinical practice in the treatment
of schizophrenia in Belgium.
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OBJECTIVE: To compare incidence rates of hyperlipi-
demia among schizophrenia patients treated with 
conventional or newer antipsychotics. METHODS: Inte-
grated claims from a large insured population were used.
Analysis included 614 individuals who: were diagnosed
with schizophrenia (ICD9 295.xx); initiated a typical
antipsychotic, or olanzapine or risperidone; had no use
of any antipsychotics in the prior 6 months. New onset
hyperlipidemia was deﬁned as either two hyperlipidemia
diagnoses (ICD9 272.xx) or prescription for lipid-
lowering agents. One-year incidence rates were compared
using logistic regressions controlling for demographics
and medical comorbidities. Cox proportional hazard
method and Kaplan-Meier survival curves of time-to-
incidence were compared between treatment groups.
RESULTS: Adjusted odds ratios of incidence of hyper-
lipidemia (based on diagnosis and/or treatment) were:
atypical vs. typical 1.684 (p = 0.32); risperidone vs.
typical 1.622 (p = 0.42); olanzapine vs. typical 1.878 
